LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Marinde J. G. Bond(Utrecht University), Cornelis J.A. Punt(University of Amsterdam), Mathijs P. Hendriks(Northwest Hospital), R-J. Swijnenburg(Amsterdam University Medical Centers), Mike S.L. Liem(Medisch Spectrum Twente), Geert Kazemier(Amsterdam Neuroscience), Helga Droogendijk(Bravis Ziekenhuis), Joost M. Klaase(University Medical Center Groningen), Karen Bolhuis(The Netherlands Cancer Institute), Aysun Komurcu(Netherlands Comprehensive Cancer Organisation), Arjen M. Rijken(Amphia Ziekenhuis), J.W.B. de Groot(Isala), Johannes H. W. de Wilt(Radboud University Nijmegen), Marc Engelbrecht(University of Amsterdam), M.J. van Amerongen(Sint Maartenskliniek), B. De Valk(Spaarne Ziekenhuis), Kees Verhoef(Erasmus MC), Koert P. de Jong(University of Padua), O. J. L. Loosveld(Amphia Ziekenhuis), Martha Lopez-Yurda(Dutch Cancer Society)
Cited by 5
Related Papers
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k
From tumour heterogeneity to advances in precision treatment of colorectal cancer
|Nature Reviews Clinical Oncology|2016|692